PARP1 and breast cancer: Although olaparib, a new PARP1 inhibitor developed by AstraZeneca, was approved by the FDA in 2018 for the treatment of breast cancer patients with hereditary BRCA gene mutations, the toxicity and treatment resistance of olaparib still exist.